2. Search Result
Search Result
Results for "

Auristatin F-d<sub>8</sub>

" in MedChemExpress (MCE) Product Catalog:

2771

Inhibitors & Agonists

1

Screening Libraries

12

Fluorescent Dye

13

Biochemical Assay Reagents

7

Peptides

7

Inhibitory Antibodies

9

Natural
Products

10

Recombinant Proteins

2607

Isotope-Labeled Compounds

5

Antibodies

16

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12522S
    PF-06380101-d8
    2 Publications Verification

    Aur0101-d<sub>8sub>; Auristatin-0101-d<sub>8sub>

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    PF-06380101-d8 is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue[1].
    PF-06380101-d<em>8</em>
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
    Aminobenzenesulfonic <em>auristatin</em> E-d<em>8</em>
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    <em>Auristatin</em> <em>F-d</em><em>8</em>
  • HY-145989
    Aminobenzenesulfonic auristatin E

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic <em>auristatin</em> E
  • HY-15582G
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .
    Auristatin E
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic <em>auristatin</em> E TFA
  • HY-RS13999
    SUB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-146227
    DNA topoisomerase II inhibitor 1

    		Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
    DNA topoisomerase II inhibitor 1
  • HY-14648S5
    Dexamethasone-d3-1

    Hexadecadrol-d<sub>3sub>-1; Prednisolone F-d<sub>3sub>-1

    		 Isotope-Labeled Compounds Cancer
    Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d3-1
  • HY-133852
    FD-1080

    		Fluorescent Dye Others
    FD-1080 is a fluorophore with both excitation and emission in the NIR-II region (Ex=1064 nm, Em=1080 nm). FD-1080 can be used for in vivo imaging .
    <em>FD</em>-1080
  • HY-15575S
    VcMMAE-d8

    MC-Val-Cit-PAB-MMAE-d<sub>8sub>; mc-vc-PAB-MMAE-d<sub>8sub>

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
    VcMMAE-d<em>8</em>
  • HY-133852A
    FD-1080 free acid
    1 Publications Verification

    		 Fluorescent Dye Others
    FD-1080 free acid is a fluorophore with both excitation and emission in the NIR-II region (Ex=1064 nm, Em=1080 nm). FD-1080 free acid can be used for in vivo imaging .
    <em>FD</em>-1080 free acid
  • HY-D2294
    FD dye 7

    		Fluorescent Dye Others
    FD dye 7 (compound 7) is an intermediate of heptamethacyanine dye fluorescent dye and can be used to synthesize dyes FD-1 and FD-2 .
    <em>FD</em> dye 7
  • HY-128570
    FD-IN-1

    		Complement System Inflammation/Immunology
    FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
    <em>FD</em>-IN-1
  • HY-148171
    L-2'-Fd4C

    		HIV HBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection
    L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity .
    L-2'-<em>Fd</em>4C
  • HY-155529
    FD1024

    		Pim Cancer
    FD1024 is PIM inhibitor (IC50s: 1.96, 38.9, 4.17 nM for PIM1, 2, 3). FD1024 can be used for research of acute myeloid leukemia. FD1024 has strong antiproliferative activity against the tested AML cell lines, with 0.16 μM, 0.12 μM, 1.05 μM, 1.39μM for EOL-1, MV-4-11, KG-1, MOLM-16 cells. FD1024 also has antitumor efficacy in mice .
    <em>FD</em>1024
  • HY-132231
    FD223

    		PI3K Apoptosis Cancer
    FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML .
    <em>FD</em>223
  • HY-15162A
    MMAE-d8
    5+ Cited Publications

    Monomethyl Auristatin E-d<sub>8sub>; Deuterated labeled MMAE

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d<em>8</em>
  • HY-155066
    FD274

    		PI3K mTOR Cancer
    FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .
    <em>FD</em>274
  • HY-134178S1
    5-Fluorouridine 5'-triphosphate-13C,19F,d1

    		Isotope-Labeled Compounds Others
    5-Fluorouridine 5'-triphosphate- 13C, 19F,d1 is deuterium and 13C-labeled 5-Fluorouridine 5'-triphosphate (HY-134178).
    5-Fluorouridine 5'-triphosphate-13C,19<em>F,d</em>1
  • HY-10844S1
    Pretomanid-d5

    PA-824-d<sub>5sub>; (S)-PA 824-d<sub>5sub>

    		 Antibiotic Bacterial Isotope-Labeled Compounds Infection Cancer
    Pretomanid-d5 is deuterated labeled Pretomanid (HY-10844). Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid-d5
  • HY-148172
    L-Fd4A

    		HIV HBV Nucleoside Antimetabolite/Analog Infection
    L-Fd4A is an adenine derivative. L-Fd4A has anti-human immunodeficiency virus (HIV) (EC50=1.5 μM) and anti-hepatitis B virus (HBV) (EC50=1.7 μM) activity. L-Fd4A has low cytotoxicity .
    L-<em>Fd</em>4A
  • HY-155180
    FD2056

    		PI3K Cancer
    FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC50s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC50s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .
    <em>FD</em>2056
  • HY-15583
    Auristatin F

    		ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    <em>Auristatin</em> F
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d<sub>8sub>; Ethmozin-d<sub>8sub>; Moracizine-d<sub>8sub>

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].
    Moricizine-d<em>8</em>(Hydrochloride)
  • HY-G0021S
    N-Desmethylclozapine-d8

    Norclozapine-d<sub>8sub>; Desmethylclozapine-d<sub>8sub>; Normethylclozapine-d<sub>8sub>

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist[1][2].
    N-Desmethylclozapine-d<em>8</em>
  • HY-G0021S1
    N-Desmethylclozapine-d8 hydrochloride

    Norclozapine-d<sub>8sub> hydrochloride; Desmethylclozapine-d<sub>8sub> hydrochloride; Normethylclozapine-d<sub>8sub> hydrochloride

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist[1][2][3].
    N-Desmethylclozapine-d<em>8</em> hydrochloride
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride

    LS 519-d<sub>8sub> dihydrochloride; Pirenzepin-d<sub>8sub> dihydrochloride; Gastrozepin-d<sub>8sub> dihydrochloride

    		 Isotope-Labeled Compounds Cancer
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine-d<em>8</em> dihydrochloride
  • HY-155996
    FD2157

    		PI3K Apoptosis Cancer
    FD2157 is a photosensitive PI3K inhibitor, with IC50s of 43 nM, 83 nM, 84 nM, 14 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ respectively. FD2157 potently inhibits cancer cell proliferation and induces cell apoptosis when exposed to 365 nm UV light .
    <em>FD</em>2157
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
    <em>Auristatin</em> E
  • HY-17037S
    Pirenzepine-d8

    LS 519-d<sub>8sub> free base; Pirenzepin-d<sub>8sub>; Gastrozepin-d<sub>8sub>

    		 Isotope-Labeled Compounds mAChR Neurological Disease Inflammation/Immunology
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d<em>8</em>
  • HY-10227S
    Bortezomib-d8

    PS-341-d<sub>8sub>; LDP-341-d<sub>8sub>; NSC 681239-d<sub>8sub>

    		 Proteasome NF-κB Apoptosis Autophagy Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].
    Bortezomib-d<em>8</em>
  • HY-13011S
    Alectinib-d8

    CH5424802-d<sub>8sub>; RO5424802-d<sub>8sub>; AF802-d<sub>8sub>

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].
    Alectinib-d<em>8</em>
  • HY-13463BS
    Avatrombopag-d8 hydrochloride

    AKR-501-d<sub>8sub> hydrochloride; E5501-d<sub>8sub> hydrochloride; YM477-d<sub>8sub> hydrochloride

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Cardiovascular Disease
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].
    Avatrombopag-d<em>8</em> hydrochloride
  • HY-14740S
    Elvitegravir-d8

    GS-9137-d<sub>8sub>; JTK-303-d<sub>8sub>; D06677-d<sub>8sub>

    		 Isotope-Labeled Compounds HIV Integrase HIV Infection
    Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d<em>8</em>
  • HY-15531S
    Venetoclax-d8

    ABT-199-d<sub>8sub>; GDC-0199-d<sub>8sub>; RG7601-d<sub>8sub>

    		 Bcl-2 Family Autophagy Cancer
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
    Venetoclax-d<em>8</em>
  • HY-15581S
    MMAD-d8

    Demethyldolastatin 10-d<sub>8sub>; MonomethylAuristatin D-d<sub>8sub>; Monomethyl Dolastatin 10-d<sub>8sub>

    		 ADC Cytotoxin Microtubule/Tubulin Cancer
    MMAD-d8D is a deuterated form of MMAD, which is a microtubule disrupting agent.
    MMAD-d<em>8</em>
  • HY-Y1309S
    1-Naphthol-d8

    Furro ER-d<sub>8sub>; NSC 9586-d<sub>8sub>; Nako TRB-d<sub>8sub>

    		 Endogenous Metabolite Others
    1-Naphthol-d8 is the deuterium labeled 1-Naphthol[1]. 1-naphthol is an excited state proton transfer (ESPT) fluorescent molecular probe[2].
    1-Naphthol-d<em>8</em>
  • HY-B0272S1
    Rifampicin-d8

    Rifampin-d<sub>8sub>; Rifamycin AMP-d<sub>8sub>

    		 Bacterial Influenza Virus Antibiotic Infection
    Rifampicin-d8 (Rifampin-d8) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.
    Rifampicin-d<em>8</em>
  • HY-N0378S
    D-Mannitol-d8

    Mannitol-d<sub>8sub>; Mannite-d<sub>8sub>

    		 Endogenous Metabolite Apoptosis Metabolic Disease
    D-Mannitol-d8 is the deuterium labeled D-Mannitol. D-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
    D-Mannitol-d<em>8</em>
  • HY-13502S
    Mitoxantrone-d8

    Mitozantrone-d<sub>8sub>; NSC 301739-d<sub>8sub>

    		 Isotope-Labeled Compounds Topoisomerase PKC Cancer
    Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].
    Mitoxantrone-d<em>8</em>
  • HY-N0007S
    Bisdemethoxycurcumin-d8

    Curcumin III-d<sub>8sub>; Didemethoxycurcumin-d<sub>8sub>

    		 Apoptosis Autophagy Cancer
    Bisdemethoxycurcumin-d8 is the deuterium labeled Bisdemethoxycurcumin. Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities.
    Bisdemethoxycurcumin-d<em>8</em>
  • HY-N0623S5
    L-Tryptophan-d8

    Tryptophan-d<sub>8sub>; Tryptophane-d<sub>8sub>

    		 Endogenous Metabolite Metabolic Disease
    L-Tryptophan-d8 is the deuterium labeled L-Tryptophan. L-Tryptophan (Tryptophan) is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3[1].
    L-Tryptophan-d<em>8</em>
  • HY-B0246S2
    Carbamazepine-d8

    CBZ-d<sub>8sub>; NSC 169864-d<sub>8sub>

    		 Sodium Channel Autophagy Mitophagy Neurological Disease Cancer
    Carbamazepine-d8 is the deuterium labeled Carbamazepine. Carbamazepine, a sodium channel blocker, is an anticonvulsant agent, with an IC50 of 131 μM[1][2].
    Carbamazepine-d<em>8</em>
  • HY-13502AS
    Mitoxantrone-d8 dihydrochloride

    Mitozantrone-d<sub>8sub>(dihydrochloride); NSC 301739-d<sub>8sub> dihydrochloride

    		 Endogenous Metabolite PKC Apoptosis Topoisomerase Orthopoxvirus Isotope-Labeled Compounds Infection Cancer
    Mitoxantrone-d8 dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
    Mitoxantrone-d<em>8</em> dihydrochloride
  • HY-90001S2
    Ritonavir-d8

    ABT 538-d<sub>8sub>; RTV-d<sub>8sub>

    		 Apoptosis HIV Protease SARS-CoV HIV Isotope-Labeled Compounds Infection Cancer
    Ritonavir-d8 is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir-d<em>8</em>
  • HY-34444S
    1,1-Dioxothiolan-d8

    Bondelane A-d<sub>8sub>; Cyclic tetramethylene sulfone-d<sub>8sub>; Cyclotetramethylene sulfone-d<sub>8sub>

    		 Isotope-Labeled Compounds Others
    1,1-Dioxothiolan-d8 is the deuterium labeled 1,1-Dioxothiolan[1].
    1,1-Dioxothiolan-d<em>8</em>
  • HY-B1955S
    4',4-Dibromobiphenyl-d8

    NSC 2098-d<sub>8sub>; PBB 15-d<sub>8sub>; p,p'-Dibromobiphenyl-d<sub>8sub>

    		 Isotope-Labeled Compounds Others
    4',4-Dibromobiphenyl-d8 is the deuterium labeled 4',4-Dibromobiphenyl[1].
    4',4-Dibromobiphenyl-d<em>8</em>
  • HY-107434S
    Molindone-d8

    (±)-Molindone-d<sub>8sub>; SPN-810M-d<sub>8sub>

    		 Isotope-Labeled Compounds Dopamine Receptor Neurological Disease
    Molindone-d8 is the deuterium labeled Molindone. Molindone hydrochloride (EN-1733A) is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses[1][2].
    Molindone-d<em>8</em>
  • HY-13593S
    Chlorambucil-d8

    CB-1348-d<sub>8sub>; WR-139013-d<sub>8sub>

    		 Isotope-Labeled Compounds DNA Alkylator/Crosslinker Cancer
    Chlorambucil-d8 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].
    Chlorambucil-d<em>8</em>

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: